Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites (SPZ-Irrad)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01082341 |
Recruitment Status :
Completed
First Posted : March 8, 2010
Last Update Posted : March 23, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Malaria | Biological: Immunization with P. vivax irradiated sporozoites | Phase 1 Phase 2 |
Title: Phase 1 and Phase 2a Clinical Trial: Immunization of human volunteers with P. vivax irr-spz. (Short name: Irrad-SPZ) Population 27 healthy adult volunteers, males and non-pregnant females, between 18-45 years of age, who fulfill inclusion/exclusion criteria (described below) as determined by clinical history and serological tests. Approximately 20 parasitized blood-donor volunteers will be required to infected Anopheles mosquitoes which will be used to immunize volunteers with a total of 1000-1500 infected mosquitoes, during 8-10 months. Afterwards challenge to prove protection.
Number of Sites: 2 Study Duration: 2 years. Subject Duration : Step1: 1-2 hours to blood donors; Step 2 and 3: 2 years to immunized volunteers Objectives Primary
• To assess the safety and protective efficacy of P. vivax irradiated sporozoite vaccination.
Secondary
- To determine the immune responses and duration elicited by the P. vivax challenge in human Fy(+) volunteers previously immunized with irr-spz, as compared with non-immunized human volunteers.
- To determine the immune responses and duration elicited by irr-spz immunization scheme in human Fy(+) volunteers; comparing it with the same immunization scheme with non irr-spz in Fy(-) participants, and also with controls exposed to the same mosquito bite scheme as that of immunization but using mosquitoes without parasite infection.
- To study new antigens potentially useful to induce pre-erythrocytic protection against P. vivax malaria infection
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 27 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Phase 1 and Phase 2a Clinical Trial:Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites |
Study Start Date : | June 2012 |
Actual Primary Completion Date : | May 2015 |
Actual Study Completion Date : | September 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: Fy(+)
14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites
|
Biological: Immunization with P. vivax irradiated sporozoites
Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use. 14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials. Other Name: P. vivax irradiated sporozoites vaccine |
Active Comparator: Fy(+) control
Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites.
|
Biological: Immunization with P. vivax irradiated sporozoites
Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use. 14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials. Other Name: P. vivax irradiated sporozoites vaccine |
Active Comparator: Fy(-)
Six Fy(-) volunteers will be exposed to infective mosquito bites.
|
Biological: Immunization with P. vivax irradiated sporozoites
Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use. 14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials. Other Name: P. vivax irradiated sporozoites vaccine |
- Three groups are considered to be intervened. Experimental, Control and Fy(-) groups. Comparison will be done between E and C groups for protective efficacy. For immune response tests E vs Fy(-),E vs Fy(-), and Fy(-) vs C, pairs will be compared. [ Time Frame: 2 years ]
- The number of subjects reporting any AEs, the occurrence of specifics AEs, and discontinuation due to AEs will be tabulated. Frequency of AEs will be cross-tabulated by group for each immunization session [ Time Frame: 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
-
• Healthy 18 to 45 years old man or non-pregnant women.
- To have the capacity to sign an informed consent in a free and voluntary way.
- Have an acceptable understanding of the clinical trial through the approval of a questionnaire regarding the information given in the consent process.
- Obligatory use of adequate contra-conceptive method from beginning of recruitment and screening time up to three months after last immunization
- Do not have chronic or acute diseases. These conditions will be determined by clinical history, physical exam and laboratory tests.
- To accept not traveling to malaria endemic areas during the clinical trial should
- To have telephone at home or mobile phone that permit permanent contact for follow up
- He (she) manifest that is willing to participated during both steps of the clinical trial.
Exclusion Criteria:
- Volunteers with less than 18 old year or more than 45 old years.
- Pregnant and suckling women will be excluded. Pregnancy will be determined both by interview, and by serum B-subunit chorionic gonadotrophin testing.
- History of moderate or severe insect, or food allergies.
- G-6PD deficiency or any Hb genetic defect (for example; sickle cell disease)
- Previous malaria infection demonstrated by think smear, PCR or specific antimalarial antibodies.
- If the subject has previously participated in a malarial vaccine trial.
- Clinical record of allergies to drug or insect bites.
- Symptoms, signs or data from laboratory test that suggests to the physician any systemic disorder like renal, hepatic, cardiovascular, pulmonary, psychiatric disorders or other illnesses that could interfere with results of clinical trial or could compromise the health of the volunteer.
- To have antibodies against hepatitis C, VIH, or hepatitis B superficial antigen and/or hepatitis B core antibodies.
- To have any abnormality in the parameters assessed by blood laboratory tests. Base-line values will be established before initiation of the clinical trial.
- Presence or history of an auto-immune disease such as; Asthma, lupus, rheumatoid arthritis, Graves's disease, Hashimoto tyroiditis, and others.
- History of surgical removal of the spleen (splenectomy).
- Volunteer with medical treatment known to alter the immune system before 3 months to recruitment, such as; cortico-steroids, chemotherapeutic agents, fludarabine, cyclosporine, tacrolimus, mycophenolate mofetil, rapamycine, ATG, alemtuzumab.
- Alcoholism or drug abuse that may interfere with social relationship of individual.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01082341
Colombia | |
Malaria Vaccine of Develepmente Center | |
Cali, Valle, Colombia |
Principal Investigator: | Socrates Herrera, MD | Malaria Vaccine Develepment Center |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Socrates Herrera Valencia, Director, Malaria Vaccine and Drug Development Center |
ClinicalTrials.gov Identifier: | NCT01082341 |
Other Study ID Numbers: |
MVDC-2008-005 SPZ IRR HUMAN ( Other Identifier: MVDC ) 5R01HL086488-02 ( U.S. NIH Grant/Contract ) |
First Posted: | March 8, 2010 Key Record Dates |
Last Update Posted: | March 23, 2018 |
Last Verified: | March 2018 |
GCP Good Clinical Practice IFAT Indirect Immunofluorescence antibody test MFA Membrane Feeding Assay N Number (typically refers to subjects) RBC Red Blood Cells |
SOP Standard Operating Procedure TBS Thick blood smear P. Vivax irradiated sporozoite vaccination. |
Malaria Protozoan Infections Parasitic Diseases Infections Mosquito-Borne Diseases |
Vector Borne Diseases Vaccines Immunologic Factors Physiological Effects of Drugs |